Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Blended Water Supplies Impact Water Treatment

Where does my water come from? The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs. The New York City water…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Where does my water come from?

The source(s) of water supplied to cooling towers, boilers, and processes may vary greatly daily or even hourly. The impact this has on water systems must be closely monitored to avoid scale, deposits, corrosion, inefficient water usage, and other negative impacts on operational costs.

The New York City water supply is a good example, providing over 1.2 billion gallons/day of domestic water to more than 8 million NYC residents, 1 million users from 4 upstate counties, and the city’s many visitors. The water system is made up of aqueducts, distribution pipes, reservoirs, and water tunnels offering a total system storage capacity of close to 550 billion gallons. There are three separate systems that bring water from upstate to the city to fit this need; the Croton, to the east of the Hudson River, and the Catskill and Delaware on the west.

What is in my water?

Since the opening of the Croton Water Filtration facility in May of 2015 water treatment professionals across the five boroughs have faced issues with a blended water supply. The neighborhoods of New York City often receive a combination of all three water supplies, the Croton, Catskill, and Delaware. Operational decisions about the City’s water supply, including the proportion of water from each of the systems, are often made on an hourly basis, creating a constantly changing chemistry of a building’s incoming water.

There is currently no formal notification system in place as to when a change in water supply might occur or what the blend could consist of. When Croton water is introduced to the system there could be areas within the same borough that are 100% Croton water or 100% Catskill/Delaware water, and others that are blended at varying percentages. Conductivity measurements are relied upon to gain an understanding of what water source you’re dealing with at each location throughout the city.

In general, the conductivity of the Catskill/Delaware supply is in the 90-100 µmho range while the conductivity of the Croton water is consistently in the 350-500 µmho range. For many facilities, when the make-up water has a conductivity greater than 100, it is assumed some level of blending is taking place. The chart below details some key differences in the inorganic chemistry of the water supplies:

How does this affect my water treatment?

From a water treatment perspective, fluctuating supply/makeup water sources present significant issues for system control. To understand this concept, it’s important to understand cycles of concentration (COC). Cooling tower cycles are typically controlled by the conductivity of the water in the system. When the conductivity reaches a predetermined set point, the controller bleeds water from the system and replaces it with fresh makeup water. The makeup water has a lower concentration of salts and dilutes the system water. With consistent makeup water, this control method is simple and quite effective because water treatment professionals can predict the levels of dissolved solids in the system water (important for inhibitor choice), determine hold times (the length of time the water stays in the system), and estimate water use.

Cooling tower treatment, for example, commonly bases the cycles of concentration calculation upon conductivity readings. The incoming city water conductivity is multiplied by the targeted number of cycles to use as the conductivity set point. Over-cycling could lead to issues with scale deposition when the concentration of dissolved solids gets above the saturation point. Under-cycling can lead to unnecessary water use, lower operational efficiency, and depending on control method, inaccurate inhibitor residuals. A constantly changing water supply makes it almost impossible to consistently maintain the targeted cycles for a specific system. This is particularly true when there is no way of knowing what type of water you could be receiving at a facility at any given time. Changing the chemistry of the makeup water also changes the target cycles. A varying water supply requires consistent on-site testing of the makeup water and an experienced water treatment professional to effectively manage the fluctuating conditions.

Chem-Aqua has the perfect blend of expertise and experience to manage your changing water demands. Contact a local representative today to review your water treatment program.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Direct-to-consumer telehealth raises spending, even as ASC investment surges

Direct-to-consumer telehealth raises spending, even as ASC investment surges

A Health Affairs analysis of commercial claims data (2011–13) found 12% of direct-to-consumer telehealth visits replaced visits to other providers and 88% represented new utilization, with net annual spending on acute respiratory illness increasing $45 per telehealth user. Separately, MobiHealthNews reported on August 31, 2026, via a HIMSSCast episode, that Erik Tellefson of Capital One said ambulatory surgery centers “represent one of the clearest growth structures in American healthcare.”

  • 01The most actionable benchmark for finance teams evaluating DTC telehealth is substitution rate, not visit growth. Health Affairs measured 12% substitution and 88% new utilization in commercial claims for acute respiratory illness.
  • 02The $45 per-user net annual spend increase in the Health Affairs analysis is small enough to hide in PMPM reporting but large enough to matter at scale, and it should be stress-tested against virtual-visit eligibility rules and repeat-use patterns.

Sep 2, 2026

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA’s new chair is a hospital CFO as Medicare reporting gets more detailed and revenue cycle work gets more technical

HFMA named Corewell Health CFO Matthew E. Cox as its national chair effective June 1, 2026, while elevating revenue cycle and reimbursement leaders to its board, according to HFMA’s GlobeNewswire announcement. The association’s own coverage of CMS’s FY 2027 IPPS/LTCH PPS final rule summary and new Medicare cost-reporting requirements such as Worksheet S-12 indicates a compliance workload that is increasingly data- and documentation-heavy for hospital finance and reporting teams. In parallel, HFMA’s certification catalog, including the Certified Hospital Cost Report Specialist (CHCRS) and Certified Specialist Payment & Reimbursement (CSPR), points to how health systems are professionalizing the skill sets needed to operationalize reimbursement policy changes. For operators, the practical consequence shows up in staffing models, audit readiness, and the data plumbing needed to produce defensible cost reports and faster revenue cycle decisions.

  • 01HFMA’s board slate now visibly includes roles that control the work: a system CFO (Corewell Health) and a chief revenue officer overseeing $7 billion in patient revenue at Orlando Health, per GlobeNewswire. That’s a signal that cost reporting and revenue cycle execution are board-level concerns, not back-office chores.
  • 02Medicare cost reporting is moving toward more granular worksheets and documentation, and each new CMS reporting requirement becomes a data-integration project before it becomes a policy memo, per HFMA’s reporting on Worksheet S-12 and its FY 2027 IPPS/LTCH PPS coverage.
  • 03HFMA’s CHCRS, CRCR, and CSPR credentials provide a concrete way to benchmark internal capability: if cost report preparation, managed care contract terms, and prior auth workflows live in different teams, credentialing can reveal where handoffs are breaking down.

Sep 2, 2026

FDA QMSR ties supplier contracts to inspection prep

FDA QMSR ties supplier contracts to inspection prep

FDA’s Quality Management System Regulation (QMSR) took effect Feb. 2, 2026, incorporating ISO 13485:2016 into 21 CFR Part 820 and shifting inspections to a process-based model under Compliance Program 7382.850, according to MD+DI. That change is starting to show up outside the quality department: medical device OEMs are being pushed to spell out documentation, audit support, and change-control responsibilities in contract manufacturing agreements, as Medical Design and Outsourcing described. Two recent partnership moves, Ratio Therapeutics expanding radiopharmaceutical manufacturing with PharmaLogic in Idaho Falls and Menicon shifting U.S. Rose K manufacturing access to three partners after concluding a prior arrangement, illustrate how multi-party supply chains now need contract terms that map directly to integrated QMS evidence. The operational consequence is simple: under CP 7382.850, a complaint, supplier nonconformance, or process change can pull investigators across CAPA, risk management, purchasing, and design records in one thread, so contracts and quality records have to be built to travel together.

  • 01Under FDA CP 7382.850, inspection risk increasingly sits in the “handoffs” between complaint handling, CAPA, supplier controls, and the Risk Management File, so quality evidence has to be assembled end-to-end, not by department.
  • 02For OEMs outsourcing manufacturing, the most useful contract test in 2026 is whether each clause produces inspectable artifacts, who owns them, where they live, and how fast they can be produced during an audit.
  • 03Multi-partner manufacturing models, like Menicon’s three-partner Rose K availability and Ratio’s capacity expansion with PharmaLogic, raise the bar on configuration control, supplier risk classification, and change notification across sites.

Sep 2, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512